register

News & Trends - Pharmaceuticals

Migraine summit marks 10-year impact on patient outcomes

Health Industry Hub | March 13, 2025 |

The Migraine World Summit (MWS), co-founded by Sydney-based migraine advocate Carl Cincinnato, marks a decade of life-changing education with the release of its first-ever 10-Year Impact Report.

The report reveals that MWS expert-led sessions and resources have helped prevent over 1.6 million migraine days worldwide, highlighting the tangible effects of informed self-advocacy and the critical role of education in migraine management.

“Migraine is not just a headache – it is a debilitating neurological disease that affects over a billion people worldwide, disproportionately impacting women and those struggling with mental health conditions,” said Carl Cincinnato, founder and co-host of the Migraine World Summit.

“As an Australian living with migraine, I’ve seen firsthand how this disease is often misunderstood and undertreated both locally and globally. Our mission has always been to reduce the global burden of migraine by providing access to world-leading experts, and this milestone proves that we are making a difference.”

The report, which draws on a decade of participant surveys and independent analysis, reveals that 56% of participants experience fewer migraine days or reduced disability. Of those who reported improvements, 9 out of 10 credit the Migraine World Summit as a key factor in their progress. Additionally, 93% of participants implement an average of 3.5 new strategies to better manage their migraines after attending, while 83% feel less isolated in their migraine journey.

The findings come at a time when migraine and women’s health disparities are gaining increasing attention. Women are three times more likely to have migraine than men, yet they often struggle to get an accurate diagnosis, face dismissive treatment and are underrepresented in migraine research. Meanwhile, the link between migraine and mental health continues to be overlooked, despite research showing that people with migraine are 2.5 to 6 times more likely to experience depression or anxiety.

“The reality is that migraine is still too often ignored—by employers, healthcare systems, and policymakers,” said Elizabeth DeStefano, co-host of the Migraine World Summit. “We’ve spent the last decade proving that when people have access to expert knowledge, they can advocate for themselves, improve their health, and regain control of their lives. But there’s still so much work to do.”

The Migraine World Summit, take place free and online from March 21–28 (AEDT), provides a rare opportunity for people living with migraine to hear directly from top specialists, researchers, and clinicians from institutions like Mayo Clinic, Albert Einstein College of Medicine, and the International Headache Society.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - Biotechnology

CSL reshapes R&D while bracing for U.S. tariffs

CSL reshapes R&D while bracing for U.S. tariffs

Health Industry Hub | July 11, 2025 |

Australia’s largest biotech company CSL is streamlining its R&D operations to enhance efficiency amidst a rapidly evolving global landscape. The […]

More


News & Trends - MedTech & Diagnostics

Australia joins Medtronic trial in fight against resistant hypertension

Australia joins Medtronic trial in fight against resistant hypertension

Health Industry Hub | July 11, 2025 |

Medtronic has launched an international clinical trial across Australia, the United States, and Europe to evaluate the feasibility of multi-organ […]

More


News & Trends - MedTech & Diagnostics

Medibank launches pharmacogenetic testing while government stalls on insurance discrimination ban

Medibank launches pharmacogenetic testing while government stalls on insurance discrimination ban

Health Industry Hub | July 11, 2025 |

Medibank has become the first Australian health insurer to pay towards pharmacogenetic testing (PGx) for eligible customers on Extras cover. […]

More


News & Trends - Pharmaceuticals

Global pledge shifts visibility and action for patients with advanced breast cancer

Global pledge shifts visibility and action for patients with advanced breast cancer

Health Industry Hub | July 11, 2025 |

Three breast cancer organisations have united internationally to demand that people living with metastatic breast cancer (MBC) are no longer […]

More


This content is copyright protected. Please subscribe to gain access.